Login
Home
Charts
Search
Watchlist
Products

Indo Borax & Chemicals Ltd

INDOBORAX·NSE
461.00-0.55%Wed, 23 Sept '26 13:54

Indo Borax & Chemicals Ltd

INDOBORAX
NSE
461.00
-0.55%
|Wed, 23 Sept '26 13:54
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,479Cr
Close
Close Price
460.80
Industry
Industry
Chemicals - Inorganic
PE
Price To Earnings
26.24
PS
Price To Sales
6.37
Revenue
Revenue
232Cr
Rev Gr TTM
Revenue Growth TTM
29.69%
PAT Gr TTM
PAT Growth TTM
45.54%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
474445503838505458416370
Growth YoY
Revenue Growth YoY%
-23.6-20.4-18.7-9.5-19.1-14.910.37.752.89.425.731.3
Expenses
ExpensesCr
373534332927404147325051
Operating Profit
Operating ProfitCr
109121691010121191320
OPM
OPM%
21.720.825.433.124.226.920.422.818.121.020.428.2
Other Income
Other IncomeCr
3333444313453
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111111110
PBT
PBTCr
121114191314131423121722
Tax
TaxCr
333545346336
PAT
PATCr
9811149910101691516
Growth YoY
PAT Growth YoY%
-22.3-39.9-9.635.02.810.2-10.5-27.277.12.241.959.3
NPM
NPM%
19.118.725.228.224.224.220.419.028.122.623.123.1
EPS
EPS
2.82.63.64.42.92.83.23.25.12.94.55.1
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
474445503838505458416370
Growth YoY
Revenue Growth YoY%
-23.6-20.4-18.7-9.5-19.1-14.910.37.752.89.425.731.3
Expenses
ExpensesCr
373534332927404147325051
Operating Profit
Operating ProfitCr
109121691010121191320
OPM
OPM%
21.720.825.433.124.226.920.422.818.121.020.428.2
Other Income
Other IncomeCr
3333444313453
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111111110
PBT
PBTCr
121114191314131423121722
Tax
TaxCr
333545346336
PAT
PATCr
9811149910101691516
Growth YoY
PAT Growth YoY%
-22.3-39.9-9.635.02.810.2-10.5-27.277.12.241.959.3
NPM
NPM%
19.118.725.228.224.224.220.419.028.122.623.123.1
EPS
EPS
2.82.63.64.42.92.83.23.25.12.94.55.1

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7067101128115144176225191175215232
Growth
Revenue Growth%
-20.4-4.351.427.2-10.225.121.928.1-15.0-8.422.929.7
Expenses
ExpensesCr
57568310897100128163149129171180
Operating Profit
Operating ProfitCr
121017201944486243464452
OPM
OPM%
17.715.317.315.716.230.527.227.522.426.220.522.3
Other Income
Other IncomeCr
3346543912162625
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111122333
PBT
PBTCr
141220242247506952596774
Tax
TaxCr
4477512141813161618
PAT
PATCr
9813181734365139435056
Growth
PAT Growth%
-31.9-13.467.830.8-3.4102.26.239.4-23.19.118.345.5
NPM
NPM%
13.312.013.313.714.723.820.722.520.424.323.324.3
EPS
EPS
2.92.54.25.55.310.711.315.812.213.315.717.6
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7067101128115144176225191175215232
Growth
Revenue Growth%
-20.4-4.351.427.2-10.225.121.928.1-15.0-8.422.929.7
Expenses
ExpensesCr
57568310897100128163149129171180
Operating Profit
Operating ProfitCr
121017201944486243464452
OPM
OPM%
17.715.317.315.716.230.527.227.522.426.220.522.3
Other Income
Other IncomeCr
3346543912162625
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
111111122333
PBT
PBTCr
141220242247506952596774
Tax
TaxCr
4477512141813161618
PAT
PATCr
9813181734365139435056
Growth
PAT Growth%
-31.9-13.467.830.8-3.4102.26.239.4-23.19.118.345.5
NPM
NPM%
13.312.013.313.714.723.820.722.520.424.323.324.3
EPS
EPS
2.92.54.25.55.310.711.315.812.213.315.717.6

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
33333333333
Reserves
ReservesCr
8491101118135170204252290332383
Current Liabilities
Current LiabilitiesCr
781098161318151816
Non Current Liabilities
Non Current LiabilitiesCr
33222223333
Total Liabilities
Total LiabilitiesCr
97106117132149190222275311357405
Current Assets
Current AssetsCr
344055728081121168201154324
Non Current Assets
Non Current AssetsCr
636662606910910010711020280
Total Assets
Total AssetsCr
97106117132149190222275311357405
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
33333333333
Reserves
ReservesCr
8491101118135170204252290332383
Current Liabilities
Current LiabilitiesCr
781098161318151816
Non Current Liabilities
Non Current LiabilitiesCr
33222223333
Total Liabilities
Total LiabilitiesCr
97106117132149190222275311357405
Current Assets
Current AssetsCr
344055728081121168201154324
Non Current Assets
Non Current AssetsCr
636662606910910010711020280
Total Assets
Total AssetsCr
97106117132149190222275311357405

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
18211151316116069-10487
Investing Cash Flow
Investing Cash FlowCr
-26-245-1626-5426-8-30-7-77
Financing Cash Flow
Financing Cash FlowCr
-4-1-2-1-1-1-3-3-3-3-3
Net Cash Flow
Net Cash FlowCr
-12-45-238-39344936-1157
Free Cash Flow
Free Cash FlowCr
8191141315115765-111106
CFO To PAT
CFO To PAT%
198.7257.68.984.177.846.031.6118.9178.3-245.8173.4
CFO To EBITDA
CFO To EBITDA%
148.5202.06.973.470.835.824.097.3162.6-227.7197.4
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
18211151316116069-10487
Investing Cash Flow
Investing Cash FlowCr
-26-245-1626-5426-8-30-7-77
Financing Cash Flow
Financing Cash FlowCr
-4-1-2-1-1-1-3-3-3-3-3
Net Cash Flow
Net Cash FlowCr
-12-45-238-39344936-1157
Free Cash Flow
Free Cash FlowCr
8191141315115765-111106
CFO To PAT
CFO To PAT%
198.7257.68.984.177.846.031.6118.9178.3-245.8173.4
CFO To EBITDA
CFO To EBITDA%
148.5202.06.973.470.835.824.097.3162.6-227.7197.4

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
9593167134502104603275185457781,479
Price To Earnings
Price To Earnings
10.411.612.47.72.96.11.36.513.312.815.526.2
Price To Sales
Price To Sales
1.41.41.61.10.41.52.61.42.73.13.66.4
Price To Book
Price To Book
1.11.01.61.10.41.20.21.31.81.62.03.8
EV To EBITDA
EV To EBITDA
7.59.29.36.50.54.78.93.99.311.717.328.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
31.829.628.827.830.346.944.941.536.644.138.638.6
OPM
OPM%
17.715.317.315.716.230.527.227.522.426.220.522.3
NPM
NPM%
13.312.013.313.714.723.820.722.520.424.323.324.3
ROCE
ROCE%
15.712.219.519.916.126.924.127.117.817.517.217.2
ROE
ROE%
10.68.412.814.412.319.817.619.913.312.713.013.0
ROA
ROA%
9.57.611.513.311.418.016.418.412.511.912.412.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
9593167134502104603275185457781,479
Price To Earnings
Price To Earnings
10.411.612.47.72.96.11.36.513.312.815.526.2
Price To Sales
Price To Sales
1.41.41.61.10.41.52.61.42.73.13.66.4
Price To Book
Price To Book
1.11.01.61.10.41.20.21.31.81.62.03.8
EV To EBITDA
EV To EBITDA
7.59.29.36.50.54.78.93.99.311.717.328.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
31.829.628.827.830.346.944.941.536.644.138.638.6
OPM
OPM%
17.715.317.315.716.230.527.227.522.426.220.522.3
NPM
NPM%
13.312.013.313.714.723.820.722.520.424.323.324.3
ROCE
ROCE%
15.712.219.519.916.126.924.127.117.817.517.217.2
ROE
ROE%
10.68.412.814.412.319.817.619.913.312.713.013.0
ROA
ROA%
9.57.611.513.311.418.016.418.412.511.912.412.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
- **Indo Borax & Chemicals is India’s dominant maker of boron-based chemicals, a 45-year-old manufacturer whose entire business rests on a single, concentrated plant in Pithampur, Madhya Pradesh. It was built on a series of firsts - the first Indian company to win BIS certification for Boric Acid and still the country’s sole producer of pharmaceutical-grade Boric Acid - and that pattern of earning regulatory or quality-based monopolies before competitors explains its approach. The company has recently undergone a complete change in ownership, with Zenrock Chemicals and a new leadership team taking charge in the fourth quarter of 2026, while the business itself remains a pure-play chemical manufacturer with near-zero debt.** # Business segments Two engines built on a single manufacturing backbone - a dominant Boric Acid franchise that supplies half of India’s demand, and a set of value-added downstream products that turn the same raw material into higher-margin agricultural and industrial chemicals. ## 1. Boric Acid: the franchise that supplies half of India **The company commands roughly 50% of the Indian Boric Acid market from a single plant, with a quality premium that no domestic competitor can match because it holds the only pharmaceutical-grade licence in the country.** - **The sole pharma-grade licence** - it is the only Indian manufacturer holding both an FDA licence and Indian Pharmacopoeia certification for Boric Acid, which means every pharmaceutical and personal-care buyer who needs that purity level must come to Indo Borax. - **First to the BIS standard** - it was the first manufacturer in India to receive BIS certification for Technical Grade Boric Acid in both powder and granular forms, and all its grades sell at a premium to competitors’ products because of that quality reputation. - **Steel drives the volume** - 55% to 60% of Boric Acid demand comes from the steel and refractory industry, so the company’s fortunes are tied to Indian steelmaking; ceramics/tiles and plywood each add another 10% to 15%. - **Pricing built on cost, not an index** - customer contracts are a mix of monthly, quarterly, and yearly arrangements, with prices set on a cost-plus and market-plus/minus basis rather than tracking any global or local commodity index. - **A 20,000-tonne anchor** - total Boric Acid capacity at Pithampur is about 20,000 tonnes per annum, of which roughly 15,000 tonnes is Technical Grade and about 900 tonnes is the high-purity IP Grade, serving a domestic market estimated at around 40,000 tonnes a year. ## 2. Downstream boron products: turning the raw material into higher-value chemicals **Using Boric Acid made in-house as the feedstock, the company manufactures a set of specialised boron derivatives - agricultural micronutrients, fire retardants, and advanced industrial chemicals - that earn better margins than the base product.** - **A fertiliser with a government licence** - Disodium Octaborate Tetrahydrate (DOT) is a boron micronutrient listed under India’s Fertilizer Control Order, and the company holds a valid fertiliser licence to make it, giving it a regulated entry into a market where Indian soil is widely boron-deficient and the government actively promotes boron use. - **Cheaper raw material than rivals** - because DOT is made from Boric Acid and the company produces that Boric Acid itself, it has a structural cost advantage over competitors who must import both the finished DOT and its raw-material inputs. - **Proven against imports** - comparative studies by IIT and CSIR found the company’s DOT to be much superior to imported products, so it competes on quality as well as import-parity pricing when tying up with fertiliser companies. - **Boron Oxide, the next build** - the company has begun dispatching Boron Oxide, a higher-value product used as an advanced binding agent in refractories and to boost thermal resistance in glass and ceramics, and is investing roughly Rs. 20 crore in a dedicated 4,000-tonne-per-annum facility at Pithampur because the user industry has accepted it well and the market is growing fast. # Manufacturing and supply chain: the single-plant model **All production runs through one state-of-the-art facility in Pithampur using in-house technology, but every ounce of raw material must be imported because India has no commercially viable boron ore reserves.** - **One plant, 106 people** - the entire manufacturing operation is concentrated at a single site in the Pithampur Industrial Area, Madhya Pradesh, with a permanent workforce of just 106 employees and technology developed entirely in-house rather than licensed from abroad. - **Entirely dependent on imported ore** - boron ores and derivatives are not commercially available in India, so the company sources all its principal raw materials - primarily Ulexite and Sulphuric Acid - from Turkey, South America, and North America under yearly, six-monthly, and quarterly contracts. - **Two quarters of cover at all times** - to hedge against price swings and supply disruptions, the company maintains a strategy of securing raw material supply for a minimum of two quarters ahead and actively diversifies across geographies to manage concentration risk. - **A byproduct that pays** - the manufacturing process yields Gypsum as a byproduct, which the company sells into cement, construction, and agriculture, turning a waste stream into a secondary revenue line. # Group structure and partners **The company changed hands completely in January 2026, with Zenrock Chemicals - a vehicle created specifically for this acquisition - and a set of Edelweiss-managed alternative investment funds taking control, backed by a new leadership team drawn from chemicals and consumer-industry veterans.** - **Bought with debt secured on the shares themselves** - Zenrock Chemicals financed the acquisition through Rs. 390 crore in non-convertible debentures and Rs. 75 crore in preference shares issued to the AIF partners, with the debentures secured by a first-ranking pledge over Zenrock’s entire shareholding in Indo Borax and over the acquirer’s own equity. - **A clean sweep of leadership** - on the day the transaction closed, a new team led by Managing Director & CEO Suresh Kalra (28 years in chemicals) and Executive Director Harsh Malhotra (nearly a decade at Amazon) was appointed, with a non-executive director bringing 38 years of entrepreneurial experience. - **A real-estate subsidiary sits alongside** - the company wholly owns Indoborax Infrastructure Private Limited, a builders-and-developers entity, and holds investment property with a fair value of about Rs. 91 crore that generated rental income of roughly Rs. 3.6 crore in FY25.

Documents — Indo Borax & Chemicals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/pn0fdrdi0rz3nnk4eldh4xyn.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/ukeiqjy5nkznvg4li9p1o92q.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/v4pba0npbzu0xcarjskseomn.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/rujxm7emct5zxohlhlt7952o.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/j91udlbd63531hpnzgeptg6q.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/u0mjpwa3ifqze3ds8l6mi32j.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/sdykroenjc4x2uwrrlaal0cs.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/yu4v9nqsvwukr1queqgmo3ne.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/44dxljtskz5lqha17m103se0.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/9r96d8pdhh9ss0iz6nis50ep.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/3mv83wdx04nlarpjwcp0wxab.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/cqdu5pwl14fy288o5skth3pm.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6l4r53ghla43tna3d471mjy4.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/mmuevs66qq4r6fn0yd8dr176.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/m9uqn23smm79vobahorg1qf6.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/1zd1q9f963sxz84h89gcxes5.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/jlkt7ey6wker4fvd4tylafr1.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/gj830pfcqywzphc7ush9goki.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/84mum8rgn1r7jqsnr4kgpoy2.pdf

Concall Transcript Summaries — Indo Borax & Chemicals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AINDOBORAX/transcript-notes/202606/pn0fdrdi0rz3nnk4eldh4xyn.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AINDOBORAX/transcript-notes/202603/ukeiqjy5nkznvg4li9p1o92q.pdf